Literature DB >> 10854958

The effect of alcohol abuse on the risk of NSAID-related gastrointestinal events.

C I Neutel1, W C Appel.   

Abstract

PURPOSE: Non-steroidal anti-inflammatory drugs (NSAIDs) are known to increase the risk of gastrointestinal (GI) complications. Excessive alcohol consumption may further increase this risk and the FDA is requiring warnings on over-the-counter (OTC) NSAIDs. Our objective is to evaluate the risk of NSAID-related GI events for persons with a history of alcohol abuse.
METHODS: This case control study used data from Saskatchewan Health. Cases consisted of 1083 patients hospitalized for severe GI events, whereas the control group consisted of 14,754 persons without such hospitalizations.
RESULTS: Five percent of cases and 1.9% of controls had a history of treatment for alcohol abuse. The presence of either NSAID use or a history of alcohol abuse led to an odds ratio (OR) of 2.9* for severe GI events, whereas the presence of both risk factors simultaneously led to an OR of 10.2* (additive would be 5.8). Similarly, the presence of ibuprofen and naproxen use, which are OTC in the USA, without alcohol abuse led to an OR of 1.9*, whereas alcohol abuse by itself led to an OR of 2.4*. The presence of both OTC NSAIDs and alcohol abuse simultaneously, led to an OR of 6.5 (additive would be 4.3). Thus with both risk factors present, the resulting risk ratio is greater than the additive risk of the separate risk factors.
CONCLUSIONS: The Food and Drug Administration (FDA) warning concerns concurrent use of alcohol with NSAIDs, whereas the present study presents the effect of long term alcohol abuse. Further research is needed to separate these two issues to allow physicians to provide the best advice to their patients. *Statistically significant at p<0.05.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10854958     DOI: 10.1016/s1047-2797(00)00040-5

Source DB:  PubMed          Journal:  Ann Epidemiol        ISSN: 1047-2797            Impact factor:   3.797


  7 in total

1.  Predischarge Injectable Versus Oral Naltrexone to Improve Postdischarge Treatment Engagement Among Hospitalized Veterans with Alcohol Use Disorder: A Randomized Pilot Proof-of-Concept Study.

Authors:  Angela Christina Busch; Meenakshi Denduluri; Joseph Glass; Scott Hetzel; Shalu P Gugnani; Michele Gassman; Dean Krahn; Brienna Deyo; Randall Brown
Journal:  Alcohol Clin Exp Res       Date:  2017-06-12       Impact factor: 3.455

2.  Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark.

Authors:  Lene Mellemkjaer; William J Blot; Henrik Toft Sørensen; Lars Thomassen; Joseph K McLaughlin; Gunnar Lauge Nielsen; Jørgen H Olsen
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

3.  Abuse of Non-opioid Analgesics in Germany: Prevalence and Associations Among Self-Medicated Users.

Authors:  Christian Rauschert; Nicki-Nils Seitz; Sally Olderbak; Oliver Pogarell; Tobias Dreischulte; Ludwig Kraus
Journal:  Front Psychiatry       Date:  2022-04-25       Impact factor: 5.435

Review 4.  Prime Drug Interplay in Dental Practice.

Authors:  Sumedha Mohan; Vivek Govila; Ashish Saini; Sunil Chandra Verma
Journal:  J Clin Diagn Res       Date:  2016-03-01

5.  Development of a Physiologically Based Pharmacokinetic Model for Prediction of Ethanol Concentration-Time Profile in Different Organs.

Authors:  Armin Sadighi; Lorenzo Leggio; Fatemeh Akhlaghi
Journal:  Alcohol Alcohol       Date:  2021-06-29       Impact factor: 2.826

6.  Approach to the pharmacological management of chronic pain in patients with an alcohol use disorder.

Authors:  Laura Murphy; Karen Wk Ng; Victoria Ch Su; Sarah Woodworth-Giroux; Todd S Levy; Beth A Sproule; Andrea D Furlan
Journal:  J Pain Res       Date:  2015-11-30       Impact factor: 3.133

7.  Gastroprotective effects of the nonsaponin fraction of Korean Red Ginseng through cyclooxygenase-1 upregulation.

Authors:  Jeong-Oog Lee; Ji Hye Kim; Sunggyu Kim; Mi-Yeon Kim; Yo Han Hong; Han Gyung Kim; Jae Youl Cho
Journal:  J Ginseng Res       Date:  2019-11-15       Impact factor: 6.060

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.